Insider Transactions in Q4 2024 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,627
-2.7%
|
$68,643
$9.75 P/Share
|
|
Dec 06
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+5.25%
|
-
|
|
Nov 26
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,187
-2.2%
|
$19,683
$9.87 P/Share
|
|
Nov 26
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,963
-2.11%
|
$17,667
$9.87 P/Share
|
|
Nov 22
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.8%
|
-
|
|
Nov 22
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.25%
|
-
|
|
Nov 18
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,077
-7.9%
|
$72,693
$9.26 P/Share
|
|
Nov 18
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
7,192
-7.4%
|
$64,728
$9.26 P/Share
|
|
Nov 18
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
14,400
-5.12%
|
$129,600
$9.26 P/Share
|
|
Nov 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,531
+15.34%
|
-
|
|
Nov 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,496
+10.58%
|
-
|
|
Nov 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,198
+9.7%
|
-
|